Skip to Main content Skip to Navigation
Journal articles

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

Abstract : Renal cell carcinoma encompass distinct diseases with different pathologic features and distinct molecular pathways. Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway alone or in combination have greatly changed clinical management of metastatic renal cell carcinoma, now competing with antiangiogenic drugs in monotherapy for first-line treatment. However, long-term response rates are low, and biomarkers are needed to predict treatment response. Quantification of PD-L1 expression by immunohistochemistry was developed as a promising biomarker in clinical trials, but with many limitations (different antibodies, tumour heterogeneity, specimens, and different thresholds of positivity). Other biomarkers, including tumour mutational burden and molecular signatures, are also developed and discussed in this review.
Complete list of metadata

Cited literature [72 references]  Display  Hide  Download
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Thursday, July 9, 2020 - 9:53:57 AM
Last modification on : Tuesday, November 23, 2021 - 2:36:21 PM
Long-term archiving on: : Monday, November 30, 2020 - 5:05:39 PM


Publisher files allowed on an open archive



Solène-Florence Kammerer-Jacquet, Antoine Deleuze, Judikaël Saout, Romain Mathieu, Brigitte Laguerre, et al.. Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. International Journal of Molecular Sciences, MDPI, 2019, 20 (7), pp.E1692. ⟨10.3390/ijms20071692⟩. ⟨hal-02119178⟩



Record views


Files downloads